In patients with colorectal cancer, the augmentation of CAFs secreting the BMP signaling antagonist Gremlin 1 is associated with poor survival, whereas CAF secreting the BMP signaling activator ISLR inhibit colorectal cancer progression [210]. This evidence concerns the gene ISLR and colorectal cancer.